Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...
Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research.
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Investor's Business Daily on MSN6h
Stock Market Correction: Trump Tariffs Triggers Sell-Off Despite Tame Inflation: Weekly ReviewThe major indexes suffered another week of sharp losses as Trump tariffs ramped up, shrugging off tame inflation.
In a shift in international diplomacy, the U.S. Department of Agriculture (USDA) has reached out to Denmark to ask whether the country can supply more eggs as the United States faces an ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback